Synaptogenix Return on Tangible Equity 2020-2025 | TAOX
Current and historical return on tangible equity values for Synaptogenix (TAOX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Synaptogenix Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2025-03-31 |
$-0.01B |
$0.01B |
-115.56% |
| 2024-12-31 |
$-0.01B |
$0.01B |
-83.87% |
| 2024-09-30 |
$-0.01B |
$0.01B |
-39.51% |
| 2024-06-30 |
$0.00B |
$0.02B |
-8.33% |
| 2024-03-31 |
$-0.01B |
$0.02B |
-42.31% |
| 2023-12-31 |
$-0.01B |
$0.03B |
-45.22% |
| 2023-09-30 |
$-0.01B |
$0.03B |
-25.81% |
| 2023-06-30 |
$-0.01B |
$0.03B |
-35.77% |
| 2023-03-31 |
$-0.01B |
$0.03B |
-16.00% |
| 2022-12-31 |
$-0.01B |
$0.04B |
-19.51% |
| 2022-09-30 |
$-0.01B |
$0.03B |
-45.90% |
| 2022-06-30 |
$-0.01B |
$0.03B |
-44.44% |
| 2022-03-31 |
$-0.01B |
$0.03B |
-37.21% |
| 2021-12-31 |
$-0.01B |
$0.03B |
-49.48% |
| 2021-06-30 |
$-0.01B |
$0.03B |
-112.50% |
| 2021-03-31 |
$-0.01B |
|
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.011B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
